REFERENCES
1. Fried, L. P.; Tangen, C. M.; Walston, J.; et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J. Gerontol. A. Biol. Sci. Med. Sci. 2001, 56, M146-56.
2. Chen, X.; Giles, J.; Yao, Y.; et al. The path to healthy ageing in China: a Peking University-Lancet Commission. Lancet 2022, 400, 1967-2006.
3. Soysal, P.; Stubbs, B.; Lucato, P.; et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing. Res. Rev. 2016, 31, 1-8.
4. Angulo, J.; El Assar, M.; Rodríguez-Mañas, L. Frailty and sarcopenia as the basis for the phenotypic manifestation of chronic diseases in older adults. Mol. Aspects. Med. 2016, 50, 1-32.
5. Xu, Y.; Wang, M.; Chen, D.; Jiang, X.; Xiong, Z. Inflammatory biomarkers in older adults with frailty: a systematic review and meta-analysis of cross-sectional studies. Aging. Clin. Exp. Res. 2022, 34, 971-87.
6. Turkel, I.; Ozerklig, B.; Yılmaz, M.; Ulger, O.; Kubat, G. B.; Tuncer, M. Mitochondrial transplantation as a possible therapeutic option for sarcopenia. J. Mol. Med. 2023, 101, 645-69.
7. Dupont, J.; Dedeyne, L.; Dalle, S.; Koppo, K.; Gielen, E. The role of omega-3 in the prevention and treatment of sarcopenia. Aging. Clin. Exp. Res. 2019, 31, 825-36.
8. Calder, P. C. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem. Soc. Trans. 2017, 45, 1105-15.
9. Sunderland, E. M.; Hu, X. C.; Dassuncao, C.; Tokranov, A. K.; Wagner, C. C.; Allen, J. G. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. J. Expo. Sci. Environ. Epidemiol. 2019, 29, 131-47.
10. Evich, M. G.; Davis, M. J. B.; McCord, J. P.; et al. Per- and polyfluoroalkyl substances in the environment. Science 2022, 375, eabg9065.
11. Stanifer, J. W.; Stapleton, H. M.; Souma, T.; Wittmer, A.; Zhao, X.; Boulware, L. E. Perfluorinated chemicals as emerging environmental threats to kidney health: a scoping review. Clin. J. Am. Soc. Nephrol. 2018, 13, 1479-92.
12. Rosen, E. M.; Kotlarz, N.; Knappe, D. R. U.; et al. Drinking water-associated PFAS and fluoroethers and lipid outcomes in the GenX exposure study. Environ. Health. Perspect. 2022, 130, 97002.
13. Tancreda, G.; Campisi, L.; Sarti, M.; Pozzo, L.; Vornoli, A. Perfluoroalkyl substances (PFAS) and lipid metabolism in experimental animal models: a scoping review on the mechanisms behind the induced hepatotoxicity. Curr. Issues. Mol. Biol. 2025, 47, 944.
14. Wielsøe, M.; Long, M.; Ghisari, M.; Bonefeld-Jørgensen, E. C. Perfluoroalkylated substances (PFAS) affect oxidative stress biomarkers in vitro. Chemosphere 2015, 129, 239-45.
15. Liu, B.; Zhu, L.; Wang, M.; Sun, Q. Associations between per- and polyfluoroalkyl substances exposures and blood lipid levels among adults - a meta-analysis. Environ. Health. Perspect. 2023, 131, 56001.
16. Salihovic, S.; Fall, T.; Ganna, A.; et al. Identification of metabolic profiles associated with human exposure to perfluoroalkyl substances. J. Expo. Sci. Environ. Epidemiol. 2019, 29, 196-205.
17. Ma, X.; Cai, D.; Chen, Q.; et al. Hunting metabolic biomarkers for exposure to per- and polyfluoroalkyl substances: a review. Metabolites 2024, 14, 392.
18. Yang, W.; Ling, X.; He, S.; et al. PPARα/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per- and polyfluoroalkyl substances: an integrated approach. Environ. Int. 2023, 178, 108138.
19. Vanden Heuvel, J. P.; Thompson, J. T.; Frame, S. R.; Gillies, P. J. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol. Sci. 2006, 92, 476-89.
20. Wolf, C. J.; Takacs, M. L.; Schmid, J. E.; Lau, C.; Abbott, B. D. Activation of mouse and human peroxisome proliferator-activated receptor alpha by perfluoroalkyl acids of different functional groups and chain lengths. Toxicol. Sci. 2008, 106, 162-71.
21. Schlezinger, J. J.; Puckett, H.; Oliver, J.; Nielsen, G.; Heiger-Bernays, W.; Webster, T. F. Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an American diet. Toxicol. Appl. Pharmacol. 2020, 405, 115204.
22. Heindel, J. J.; Blumberg, B.; Cave, M.; et al. Metabolism disrupting chemicals and metabolic disorders. Reprod. Toxicol. 2017, 68, 3-33.
23. Le Magueresse-Battistoni, B.; Vidal, H.; Naville, D. Environmental pollutants and metabolic disorders: the multi-exposure scenario of life. Front. Endocrinol. 2018, 9, 582.
24. Baumert, B. O.; Maretti-Mira, A. C.; Walker, D. I.; et al. Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents. Commun. Med. 2025, 5, 430.
25. Gomis, M. I.; Vestergren, R.; Borg, D.; Cousins, I. T. Comparing the toxic potency in vivo of long-chain perfluoroalkyl acids and fluorinated alternatives. Environ. Int. 2018, 113, 1-9.
26. Wu, B.; Yu, H.; Huang, H.; et al. Efficient biodegradation and detoxification of 6:2 fluorotelomer sulfonic acid by Phanerochaete chrysosporium: insights into enzymatic mechanisms and reduced ecotoxicity. Chem. Eng. J. 2026, 529, 172664.
27. Calder, P. C. Very long-chain n-3 fatty acids and human health: fact, fiction and the future. Proc. Nutr. Soc. 2018, 77, 52-72.
28. Ferri, E.; Marzetti, E.; Calvani, R.; Picca, A.; Cesari, M.; Arosio, B. Role of age-related mitochondrial dysfunction in sarcopenia. Int. J. Mol. Sci. 2020, 21, 5236.
29. Kam, Y.; Winer, L.; Romero, N. Chain length-dependent mitochondrial toxicity of perfluoroalkyl carboxylic acids: insights from Mito Tox Index evaluation. Front. Toxicol. 2025, 7, 1582891.
30. Jia, X.; Liu, W.; Ling, X.; et al. Sex and obesity influence the relationship between perfluoroalkyl substances and lean body mass: NHANES 2011-2018. Heliyon 2024, 10, e35888.
31. Huang, Y.; Wang, C.; Cui, H.; Sun, G.; Qi, X.; Yao, X. Mitochondrial dysfunction in age-related sarcopenia: mechanistic insights, diagnostic advances, and therapeutic prospects. Front. Cell. Dev. Biol. 2025, 13, 1590524.
32. Serhan, C. N.; Levy, B. D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J. Clin. Invest. 2018, 128, 2657-69.
33. Chiang, N.; Serhan, C. N. Specialized pro-resolving mediator network: an update on production and actions. Essays. Biochem. 2020, 64, 443-62.
34. Bischoff-Ferrari, H. A.; Gängler, S.; Wieczorek, M.; et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nat. Aging. 2025, 5, 376-85.
35. McGlory, C.; Calder, P. C.; Nunes, E. A. The influence of omega-3 fatty acids on skeletal muscle protein turnover in health, disuse, and disease. Front. Nutr. 2019, 6, 144.
36. Kim, J.; Kim, M.; Won, C. W.; Park, Y. Erythrocyte levels of n-3 polyunsaturated fatty acids and incidence of frailty after a 6-year follow-up: the Korean frailty and aging cohort study. Front. Nutr. 2025, 12, 1569832.
37. Gagesch, M.; Wieczorek, M.; Vellas, B.; et al. Effects of vitamin D, omega-3 fatty acids and a home exercise program on prevention of pre-frailty in older adults: the DO-HEALTH randomized clinical trial. J. Frailty. Aging. 2023, 12, 71-7.
38. Hashidate-Yoshida, T.; Harayama, T.; Hishikawa, D.; et al. Fatty acid remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport. Elife 2015, 4, e06328.
39. Domingo, J. L. Health risks of dietary exposure to perfluorinated compounds. Environ. Int. 2012, 40, 187-95.
40. O’Donnell, V. B. New appreciation for an old pathway: the lands cycle moves into new arenas in health and disease. Biochem. Soc. Trans. 2022, 50, 1-11.
41. Meng, L.; Yang, R.; Wang, D.; et al. Specific lysophosphatidylcholine and acylcarnitine related to sarcopenia and its components in older men. BMC. Geriatr. 2022, 22, 249.
42. Meng, L.; Shi, H.; Wang, D. G.; et al. Specific metabolites involved in antioxidation and mitochondrial function are correlated with frailty in elderly men. Front. Med. 2022, 9, 816045.
43. Takagi, S.; Maeda, K.; Takemura, M.; et al. Low plasma lysophosphatidylcholine levels are associated with reduced handgrip strength in older outpatients. Geriatr. Gerontol. Int. 2026, 26, e70281.
44. Sevastou, I.; Kaffe, E.; Mouratis, M. A.; Aidinis, V. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA2/LPC and ATX/LPA axes. Biochim. Biophys. Acta. 2013, 1831, 42-60.
45. Zou, Y.; Kim, D. H.; Jung, K. J.; et al. Lysophosphatidylcholine enhances oxidative stress via the 5-lipoxygenase pathway in rat aorta during aging. Rejuvenation. Res. 2009, 12, 15-24.
